Company News

NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. ANY FAILURE TO COMPLY WITH THIS RESTRICTION MAY CONSTITUTE A VIOLATION OF UNITED STATES SECURITIES LAWS

Avicanna Inc. (" Avicanna " or the " Company ") (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a commercial stage, international biopharmaceutical company focused on the commercialization of evidence-based, cannabinoid-based products, is pleased to announce the filing of its interim financial statements for the three-month period ending March 31, 2022 (" Q1 2022 ") and the transition of the role of Chief Financial Officer.

"We are pleased to report on our continued progress and global commercialization efforts where we primarily focused on, and achieved, growth of our four brands in the Canadian marketplace. We also pursued continuous optimization of our operations which was demonstrated by significant cost reductions over the quarter, with the goal of self-sufficiency," stated Aras Azadian, CEO at Avicanna Inc.

Q1 2022 highlights:

Approximately 35,000 products sold representing a 41% increase in sales over last quarter and representing a 765% increase over Q1 2021. This was driven by a 44% increase in the number of Canadian product listings over the last quarter across medical and adult use channels.

Revenue of $1.04M, representing 283% increase in revenue over Q1 2021 and $0.01 net income per share compared to ($0.14) net loss per share in Q1 2021.

On-going cost reduction , resulting in $2M SG&A and a 28% reduction compared to $2.85M SG&A in Q1 2021.

Entered Supply Agreement with Chilean based pharmaceutical company Knop Laboratorios S.A . to supply Aureus branded products.

Changes to the board and executive team with the appointment of two experienced pharmaceutical executives, Eileen McCormack to the Board of Directors and Stephen Kim as the Chief Legal Officer.

Commenced Epidermolysis Bullosa Studies with the Hospital for Sick Children. The study led by Dr. Elena Pope is designed to analyze the efficacy of the Company's dermatological products on a rare skin disease.

Closed a $2.5M, non-brokered private placement at $0.35 cents per unit, where each common share would entitle the holder to half warrant exercisable at $0.40 cents per share.

Advancements in the pharmaceutical and medical cannabis pipeline, including the completion of the company's first international drug dossier for Trunerox™ in Brazil and the advancement of several medical cannabis pipeline products including water soluble formulations.

Other highlights subsequent to Q1 2022

Entered into Exclusive License and Supply Agreement with South American based pharmaceutical company, to commercialize up to four (4) of Avicanna's proprietary cannabinoid-based pharmaceutical preparations. Avicanna may possibly earn up to $1.3M CAD in initial licensing fees through achieving various milestones.

Closed $1.5M strategic private placement with lead investor Ei. Ventures, Inc., a technology company which seeks to empower mental wellness through psychoactive compounds, nutraceuticals, and technology, and with participation from other investors.

Expanded RHO Phyto TM formulary with Cannabigerol-based (" CBG ") products into the Canadian market, including oral, sublingual, and transdermal formulations which is anticipated to be made available through various medical and adult-use channels across Canada by Q3 2022.

Entered Importation & Distribution Agreement with Bio-Gate AG in Germany, to expand derma-cosmetics Brand Pura H&W™ into the European Union. Pura H&W's evidence-based derma-cosmetics portfolio will be commercialized through Bio-Gate's existing distribution channels with initial launches planned for Germany, Austria, and Switzerland in Q2 2022.

CFO Transition

The Company has accepted the resignation of its Chief Financial Officer, Dave Sohi, effective May 18, 2022. He will leave to pursue another opportunity and will for a period provide transition advisory services to the Company. The Company is pleased to announce Mr. Phillip Cardella, CPA, CA to the position of Interim Chief Financial Officer effective May 18, 2022. Previously, Mr. Cardella held the position of Senior Vice President of Finance at the Company, and prior to joining the Company practiced accounting with MNP LLP, one of the largest full service professional accountancy and business advisory firms in Canada.

"We want to thank Dave for his 5 years of service where he helped deliver our common vision into a commercial stage multinational company and helped weather the many challenges associated with building a company operating in a novel and regulated industry. We wish Dave all the best in his future endeavours," stated Azadian. "We are also delighted that Phil is able to assume the role of Interim CFO with the perspectives of, and familiarity with, the Company that only someone that has as already been working here can have," continued Azadian.

About Avicanna Inc.

Avicanna is a commercial-stage international biopharmaceutical company focused on the advancement and commercialization of evidence-based cannabinoid-based products for the global medical and pharmaceutical market segments. Avicanna has an established scientific platform including R&D and clinical development that has led to the commercialization of more than thirty products across various market segments:

Medical Cannabis & Wellness Products: Marketed under the RHO Phyto™ brand these medical and wellness products are a line of pharmaceutical-grade cannabinoid products containing varying ratios of cannabidiol ("CBD") and tetrahydrocannabinol ("THC"). The product portfolio contains a full formulary of products including oral, sublingual, topical, and transdermal deliveries that have controlled dosing, enhanced absorption and stability studies supported by pre-clinical data. The formulary is marketed with consumer, patient and medical-community education and training.

Pharmaceutical Pipeline: Leveraging Avicanna's scientific platform, vertical integration, and real-world evidence, Avicanna has created a pipeline of patent-pending drug candidates that are indication-specific and in various stages of clinical development and commercialization. These cannabinoid-based drug candidates look to address unmet medical needs in the areas of dermatology, chronic pain, and various neurological disorders. Avicanna's first pharmaceutical preparation (Trunerox™) is in the drug registration stage in South America.

Click to watch Avicanna's Corporate Video 2022

SOURCE Avicanna Inc.

Stay Connected

For more information about Avicanna, visit www.Avicanna.com, contact Ivana Maric by email at info@Avicanna.com or follow us on social media on LinkedIn , Twitter , Facebook or Instagram .

The Company posts updates through videos from the official Company YouTube channel.

Cautionary Note Regarding Forward-Looking Information and Statements

This news release contains "forward-looking information" within the meaning of applicable securities laws. Forward-looking information contained in this news release may be identified by the use of words such as, "may", "would", "could", "will", "likely", "expect", "anticipate", "believe, "intend", "plan", "forecast", "project", "estimate", "outlook" and other similar expressions. Forward-looking information contained in this news release includes, without limitation, statements related to the Offering, the use of the proceeds of the Offering, the receipt of all approvals of the Toronto Stock Exchange in connection with the Offering, statements with respect to the Company's future business operations, potential collaborations, the opinions or beliefs of management and future business goals. Although the Company believes that the expectations and assumptions on which such forward looking information is based are reasonable, undue reliance should not be placed on the forward-looking information because the Company can give no assurance that they will prove to be correct. Actual results and developments may differ materially from those contemplated by these statements. Forward-looking information is subject to a variety of risks and uncertainties that could cause actual events or results to differ materially from those projected in the forward-looking information. Such risks and uncertainties include, but are not limited to, current and future market conditions, including the market price of the common shares of the Company, and the risk factors set out in the Company's annual information form dated March 31, 2022, filed with the Canadian securities regulators and available under the Company's profile on SEDAR at www.sedar.com. The statements in this news release are made as of the date of this release. The Company disclaims any intent or obligation to update any forward-looking information, whether as a result of new information, future events or results or otherwise, other than as required by applicable securities laws.


Primary Logo

News Provided by GlobeNewswire via QuoteMedia

AVCN:CA
Mycotopia Therapies Inc. Update on Ei.Ventures and Strategic Investments

Mycotopia Therapies Inc. Update on Ei.Ventures and Strategic Investments

Mycotopia Therapies Inc. (OTC Pink: TPIA), a biopharma company focused on research, technology, and the development of medical psychedelics, and Ei.Ventures Inc., a technology company empowering mental wellness through psychoactive compounds, nutraceuticals and web 3.0, are pleased to announce several strategic investments to advance the combined company's business plan. Ei.Ventures completed its Regulation A+ financing round on March 22, 2022 after announcing plans to go public in a $360 million transaction with Mycotopia Therapies on December 07, 2021.

The combined company will be renamed PSLY.COM and focus its efforts on developing fungi and plant based Botanical Psychedelic API and Therapeutics instead of single molecule synthetic drugs with the belief that research will continue to confirm the importance of a synergistic approach. This will set PSLY.COM apart from virtually every other company in the space developing synthetic versions of Psilocybin. Ei.Ventures holds the IP for the extraction process of three botanical potential API compounds, Psilocybin, DMT and MDMA. PSLY.COM plans to further develop this API and file a Drug Master File with the FDA, which will provide the opportunity to potentially sell the API to other organizations while protecting its IP.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
Avicanna Announces Closing of Strategic Private Placement

Avicanna Announces Closing of Strategic Private Placement

NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. ANY FAILURE TO COMPLY WITH THIS RESTRICTION MAY CONSTITUTE A VIOLATION OF UNITED STATES SECURITIES LAWS

Avicanna Inc. (" Avicanna " or the " Company ") (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a commercial stage, international biopharmaceutical company focused on the commercialization of evidence-based, cannabinoid-based products, is pleased to announce that it has closed a strategic non-brokered private placement offering of 4,210,931 ‎‎units of the Company (the " Units ") at a price of $0.35 per Unit for aggregate gross proceeds of approximately $1.475 million (the " Offering "). Each Unit is comprised of one common share in the capital of the Company (each, a " Common Share ") and one-half of one (0.5) Common Share purchase warrant of the Company (each whole warrant, a " Warrant "). Each Warrant shall entitle the holder thereof to acquire one (1) Common Share at an exercise price of $0.40 per share, subject to adjustment in certain events, for a period of 36 months.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
Avicanna Expands RHO PhytoTM Formulary with the Introduction of Cannabigerol  Products into the Canadian Market

Avicanna Expands RHO PhytoTM Formulary with the Introduction of Cannabigerol Products into the Canadian Market

Avicanna introduces the rare cannabinoid CBG into its RHO Phyto product formulary which includes oral, sublingual, and transdermal formulations

RHO Phyto CBG products will be made available through various medical and adult-use channels across Canada by Q3 2022

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
Avicanna Enters into Exclusive License and Supply Agreement with Major South American Pharmaceutical Company

Avicanna Enters into Exclusive License and Supply Agreement with Major South American Pharmaceutical Company

Avicanna Inc. ("Avicanna" or the "Company") (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a biopharmaceutical company focused on the development and commercialization of plant-derived medical and pharmaceutical cannabinoid-based products, is pleased to announce that it has entered into an exclusive license and supply agreement with an established South American pharmaceutical company to commercialize up to four (4) of Avicanna's proprietary cannabinoid-based pharmaceutical preparations.

The intellectual property related to Avicanna's proprietary cannabinoid-based pharmaceutical preparations was originally developed through the company's well established drug delivery platform and further studied through various Canadian research collaborations where the formulations demonstrated stability and bioavailability. The pharmaceutical form of these formulations was then manufactured in Colombia, through the Company's global vertical integration, where the cannabinoid raw material is also sourced from the Company's cultivation and extraction infrastructure.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
Avicanna Expands its Derma-Cosmetics Brand Pura H&W into the European Union through a Partnership with Bio-Gate AG

Avicanna Expands its Derma-Cosmetics Brand Pura H&W into the European Union through a Partnership with Bio-Gate AG

The exclusive distribution agreement includes 5 SKUs from Pura H&W's evidence-based derma-cosmetics portfolio

The products will be commercialized through Bio-Gate's existing distribution channels with initial launches planned for Germany, Austria, and Switzerland in 2022

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less

Canopy Growth Kicks Off Summer Long Weekends with Exciting New Product Line-Up

Canadian cannabis market leader introduces new offerings across its house of brands 7ACRES, Ace Valley, Deep Space and Doja

SMITHS FALLS, ON , May 20, 2022 /CNW/ - Canopy Growth Corporation ("Canopy Growth" or the "Company") (TSX: WEED) (NASDAQ: CGC), a world-leading diversified cannabis, hemp, and cannabis device company, today unveiled a line-up of new offerings across its premium brand portfolio – 7ACRES, Ace Valley, Deep Space and Doja. With select products releasing just in time for the first long weekend of the summer, including the release of its first large format premium flower offering for the recreational market, Doja 91K 14g, this new line-up builds on the Company's continued commitment to product innovation and meeting evolving consumer demand, while cementing Canopy's leadership position in the premium flower market.

News Provided by Canada Newswire via QuoteMedia

Keep reading...Show less
pair of hands holding cannabis buds

Lift Expo Show Floor Marked by Calls for Cannabis Action and Unity

The most recent edition of the Lift & Co. Expo, held this past weekend in Toronto, brought multiple calls to action among cannabis industry stakeholders.

In panels at the show and in conversations with the Investing News Network (INN), experts used this year’s event to urge all types of cannabis companies to collaborate in high-level lobbying.

During the event, a distinct theme appeared: the need for firms in the cannabis market to better advocate for themselves in front of the Canadian government.

Keep reading...Show less

Trulieve Celebrates Two Medical Dispensary Openings in West Virginia

South Charleston and Parkersburg locations both opening on Saturday, May 21 at 10 a.m.

Trulieve Cannabis Corp. (CSE: TRUL) (OTCQX: TCNNF) ("Trulieve" or "the Company"), a leading and top-performing cannabis company in the United States today announced the grand opening of its third and fourth medical dispensaries in West Virginia . Located at 4701 MacCorkle Ave. SW in South Charleston and 152 Park Shopping Center in Parkersburg both dispensaries will open at 10 a.m. on Saturday, May 21, 2022 .

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less

American Green, Inc. Purchases 40,000 square foot Cannabis Grow Building for $3,750,000

The building appraised for $5,300,000 and gives American Green total equity of $2,673,000; over 50% of the property value


May 18, 2022 - American Green, Inc. (ERBB:OTC) has purchased the 40,000 square foot building known as American Green's "Cypress Chill" cannabis facility located at 2325 W. Cypress St. Phoenix, AZ. 85009.  The building sits on a 62,000 square foot site and was previously leased by ERBB in August 2021 with an option to buy. American Green has exercised its option to buy the building and now owns it. The purchase price was set at $3.75 million at the time of the signing of the lease last year. Recently, the building was professionally appraised for $5.3 million, giving American Green $1.55 million of additional equity, at the time of closing. When added to the down payment of $1.123 million, there is now a total of $2.673 million of equity in the new "Cypress Chill" cannabis grow building.

News Provided by NewMediaWire via QuoteMedia

Keep reading...Show less

Canopy Growth Announces Plan to Acquire Jetty Extracts

Broadens Canopy Growth's Portfolio of Premium Brands with Significant Opportunities to Scale Across North America

Canopy Growth Corporation ("Canopy Growth" or "the Company") (TSX: WEED) (NASDAQ: CGC) and Lemurian, Inc. ("Jetty"), a California -based producer of high-quality cannabis extracts and pioneer of clean vape technology, announced today that they have entered into definitive agreements (the "Agreements") providing Canopy Growth, by way of a wholly-owned subsidiary ("Canopy Sub"), the right to acquire, upon federal permissibility of THC in the U.S. or earlier at Canopy Growth's election, up to 100% of the outstanding capital stock of Jetty.

News Provided by Canada Newswire via QuoteMedia

Keep reading...Show less
AgriFORCE Growing Systems Completes Acquisition of Food Production & Processing IP from Manna Nutritional Group

AgriFORCE Growing Systems Completes Acquisition of Food Production & Processing IP from Manna Nutritional Group

AGRIFORCE Growing Systems Ltd. ("the Company") (NASDAQ: AGRI; AGRIW) an intellectual property (IP)-focused AgTech company dedicated to advancing sustainable cultivation and crop processing across multiple verticals, today announced it has completed the previously announced acquisition of the intellectual property of Manna Nutritional Group (MNG). The IP encompasses patent-pending technologies to naturally process and convert grain, pulses and root vegetables, resulting in low-starch, low-sugar, high-protein, fiber-rich baking flour products, as well as a wide range of breakfast cereals, juices, natural sweeteners and baking enhancers. The core process is covered under a pending patent application in the U.S. and key international markets.

Independent lab testing indicates that MNG's soft white wheat baking flour contains over 30 times the fiber, 3 times the protein, and more than 80% less starch than conventional flour without compromising taste, texture and quality [1] . The Company's initial focus is on wheat, in which the flour has applications for baked goods, breads and snacks.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less

Latest Press Releases

Related News

×